RavenQuest BioMed (CSE:RQB) announced it signed a memorandum of understanding with the Fort McMurray #468 First Nation collaborate in the development, operation, and financing of a purpose-built facility for the production of cannabis.

As quoted in the press release:

RavenQuest has developed an indigenous-centered, end-to-end solution for cannabis production and sale on sovereign land.  RavenQuest will provide its expertise to deliver the technical know-how, staff resources, and financing opportunities as they relate to the development of the Production Facility, initially sized at 24,000 square feet.  In consideration, RavenQuest will receive a thirty percent (30%) ownership interest in such a facility.

The parties intend that the Production Facility will rapidly expand from its initial development to a maximum of 250,000 square feet.  Under such an arrangement RavenQuest will be granted the rights to a perpetual stream of a portion of cannabis produced at the Production Facility.  Any joint venture arrangement will include provisions for the continued development and expansion of the production facility.

“This MOU represents a key milestone for our organization,” said George Robinson, CEO of RavenQuest.  “We intend to emerge as the trusted provider of choice for Indigenous Peoples’ Cannabis industry partnerships across Canada.  Our work in this area reflects a high level of understanding of the concerns and issues facing Indigenous communities across Canada.  With the right partners, we see cannabis as a tremendous opportunity for economic diversification, self-reliance, employment and harm reduction within Indigenous communities.  This agreement is designed to deliver on all of these fronts, providing for a mutually beneficial arrangement for FM 468 and RavenQuest moving forward.”

Click here to read the full press release.

Source: globenewswire.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less